Physician profile
Cheryl A Richards
NPI 1215985015
$16,390.60
in general payments reported to CMS, 2019-2025
70 companies · $2,739 in 2025
The $2,739 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $1,464 · 2021: $2,946 · 2022: $2,397 · 2023: $2,572 · 2024: $2,402 · 2025: $2,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,571 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,570.51 |
| Education | $141.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.99 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,284.73 | 2021 | |
| Novo Nordisk INC | $1,233.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,074.44 | 2019-2025 | |
| Lilly USA, LLC | $1,004.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $829.03 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $727.66 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Baxter Healthcare | $693.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $603.21 | 2019-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $563.96 | 2023-2025 | Gemtesa, Kynmobi |
| Merck Sharp & Dohme LLC | $546.41 | 2019-2024 | Belsomra, Steglatro, Gardasil |
| Glaxosmithkline, LLC. | $517.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $507.87 | 2024-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $483.97 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.81 | 2019-2025 | Jardiance |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.